Descrizione del progetto
Sarà presto più accessibile uno strumento diagnostico potenziato per individuare numerose malattie
DNA e RNA sono talmente noti da essere diventati argomento di conversazione al bar. I nuovi attori in gioco sono i microRNA (miRNA). Dalla loro fortuita scoperta all’inizio degli anni '90, sono noti ad oggi oltre 2 000 miRNA negli esseri umani che si ritiene regolino circa un terzo dei geni del genoma. Questi pezzetti di RNA, circa 25 nucleotidi in lunghezza, regolano funzioni cellulari fondamentali, tra cui lo sviluppo, la differenziazione, la crescita e il metabolismo. Patologie diverse come cancro, epatopatie e le malattie legate all’età, sono state tutte collegate ad un malfunzionamento dei miRNA. LIVELMIA sta sviluppando un piano per introdurre sul mercato la propria tecnologia per le analisi dei miRNA. Una tecnologia diagnostica più rapida ed economica incentiverà la diffusione generalizzata in cliniche e ospedali a livello globale.
Obiettivo
MicroRNAs (miRNAs) are a class of newly discovered biomolecules implicated in numerous biological systems and in common human diseases (e.g. cancer, Alzheimer, osteoarthritis). It has been shown that MiRNAs are biomarkers with great diagnostic and prognostic value. MiRNAs can be the next generation targets for diagnostics and therapeutics and this is reflected in the miRNA analysis market which is forecasted to have a CAGR of 23.4% in the coming years. Unfortunately, miRNAs are very difficult to detect and measure. The methods we have today are complex, expensive and time consuming. These limitations are restricting the use of miRNA in clinics and hospitals for diagnostic medicine.
LIVELMIA is an answer to these problems. We has succeeded in developing a disruptive innovative method for high-throughput miRNAs analyses, that allows a general improvement in terms of cost, easy-of-use and accuracy. We have cut down the time required by nearly a factor of 2, bringing the total analysis time down from 6 hours to 3 hours. Furthermore LIVELMIA has a high specificity making it ideal in diagnostics to ensure quality readings in any condition. LIVELMIA is a chemical assay kit for quantification of miRNAs on various types of samples (blood, biopsies, cells) with applications in the field of health research and diagnostics medicine. Our ultimate goal is helping biomedical researchers to improve miRNA studies and move miRNA analysis from laboratory to the clinic to bring profound benefits to public health.
Today we have a TRL6/7 prototype. We are gaining considerable interest from potential customers, dealers and stakeholders. We have filed for a patent in 2018 and we are now submitting this Phase 1 proposal in order to study the feasibility and develop a business plan for LIVELMIA, where we intend to study the best segments for exploitation, our pricing strategy, costs, etc.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
40124 BOLOGNA
Italia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.